ERBB2 and neoplasm: Through promoting ErbB2 ubiquitylation, USP2 inhibitor is expected to augment the pro-degradation effects of HSP90 inhibitors toward ErbB2 within their respective therapeutic windows, thus eliciting potent anti-tumor effects with tolerable adverse side effects, which warrants further investigations and clinical evaluations.